As China continues to inch ahead of competition in terms of trial initiations, immunology and metabolic disease trials attract sponsor eyes.
As the first half of 2026 draws to a close, experts at Arena International’s OCT East Coast reflect on the key trends shaping the sector.
BioMarin Pharmaceutical has reported that its pivotal Phase III ENERGY 3 trial assessing BMN 401 in children aged one to 12 years with ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) ...
Today, 20 May, marks Clinical Trials Day. Editor Abigail Beaney spoke with CML patient Mel Mann who was one of the first patients to receive Gleevac.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results